Ivosidenib after stem cell transplant for IDH1-mutated AML or MDS
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether taking ivosidenib after a stem cell transplant can help prevent leukemia from coming back in people with a specific gene change called IDH1. It may be an option if you have AML or MDS with that mutation and are recovering from transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have acute myeloid leukemia (AML) or a high-risk myelodysplastic syndrome (MDS).
- Your cancer cells must have a specific change in the IDH1 gene (called an IDH1 mutation).
- You have already had a stem cell transplant (also called a bone marrow transplant).
- You do not have severe graft-versus-host disease (GvHD) that requires high-dose steroids (more than 1 mg per kg of prednisolone daily).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (venetoclax, ivosidenib, and azacitidine) for people newly diagnosed with a specific type of AML that has an IDH1 mutation. The goal is to see if this mix works better than standard treatments.
This trial tests a targeted pill called ivosidenib for people with a specific type of bile duct cancer (IDH1-mutated) who have completed surgery and chemotherapy. The goal is to see if taking ivosidenib as a maintenance therapy helps keep the cancer from coming back.
This study tests whether a daily pill called ivosidenib can help prevent AML from coming back after a stem cell transplant. It is for people whose AML has a specific IDH1 gene change and who are planning to have a transplant.
This trial tests whether taking ivosidenib as a maintenance drug (to keep the cancer in remission) works better than standard care for patients with IDH1-mutated AML or high-risk MDS who cannot undergo a bone marrow transplant. Ivosidenib is a targeted drug that blocks a specific mutation found in your cancer.
This trial tests an oral drug (ivosidenib) for people with IDH1-mutated cancers who also have liver or kidney problems. It aims to find the right dose and see how safe and effective it is for these patients.
This Phase 1/2 study tests whether the medicines ivosidenib and venetoclax (with or without azacitidine) can help people with certain “IDH1-mutated” blood cancers like AML or high-risk MDS. It’s meant for patients whose disease has come back, doesn’t respond, or who can’t safely get standard chemotherapy.
Hear when a new MDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.